Now Available: Diagnostics Year in Review. Click to Download Report.
Illumina Ventures, an independently managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. The latest fund is anchored by Illumina, Inc. (Nasdaq: ILMN), with the majority of the total committed capital from other strategic and financial investors, ...
Walking Fish Therapeutics, a leader in B cell engineering, today announced the close of $50M Series A financing— led by investors including Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. “Walking Fish’s financial backing, combined with its high...
Alamar Biosciences, Inc., a precision proteomics company that brings both ultra-high sensitivity and massively parallel scale to proteomic analysis, announced today that it has closed its $80 million Series B financing round, bringing its total funding to $110 million. “Alamar has made great strides in developing its novel technologies. This financing will position Alamar to complete the develo...
Today, we are proud to announce that we have raised $60 million in a Series C financing — just more than a year after our Series B close. In addition, we have acquired GeneMatters, a leading telehealth genetic counseling and software solutions company, and we welcome their team to the Genome Medical family.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
